Scientific Publications by FDA Staff
Biomark Med 2014 Jan;8(1):85-94
Urinary biomarkers track the progression of nephropathy in hypertensive and obese rats.
Zhang Q, Davis KJ, Hoffmann D, Vaidya VS, Brown RP, Goering PL
AIMS: To determine whether urinary biomarkers of acute kidney injury can be used to monitor the progression of chronic kidney injury in a rat model of hypertension and obesity. MATERIALS & METHODS: A suite of novel urinary biomarkers were used to track the progression of kidney damage in SHROB and SHR-lean rats. RESULTS: Urinary albumin, NAG, clusterin, osteopontin, RPA-1 and fibrinogen levels were significantly elevated over time and were closely associated with the severity of histopathologically determined nephropathy in both SHROB and SHR-lean rats. CONCLUSION: Urinary biomarkers, such as albumin, fibrinogen, NAG, clusterin, RPA-1 and osteopontin, may serve as useful tools to track the progression of chronic kidney disease associated with hypertension and obesity.
|Category: Journal Article|
|PubMed ID: #24325231||DOI: 10.2217/bmm.13.106|
|Includes FDA Authors from Scientific Area(s): Medical Devices Toxicological Research|
|Entry Created: 2013-12-12||Entry Last Modified: 2014-11-18|